Dr. Mark Lim
About Dr. Mark Lim
Dr. Mark Lim, Executive Vice President and CSO, is a prominent figure in the biotechnology industry with over 20 years of experience, known for his significant contributions to proteomics and autoimmune disease research.
Dr. Mark Lim Executive Vice President and CSO
Dr. Mark Lim is currently the Executive Vice President and Chief Scientific Officer (CSO). With over two decades in the biotechnology industry, he brings extensive expertise and leadership to his role. Throughout his career, Dr. Lim has made significant contributions to various projects, leveraging his vast knowledge and skills to drive advancements within his organization. His experience spans multiple areas in biotechnology, making him a valuable asset to his company.
Education and Ph.D. at Boston University
Dr. Mark Lim earned his Ph.D. in Biology from Boston University. During his doctoral studies, he focused on developing novel reversible colorimetric and luminescent metal chelate-based protein dyes for proteomics. His research and academic background provided a strong foundation for his subsequent contributions to the biotechnology industry.
Directed NIH-Supported Autoantigen Biomarker Project
Dr. Mark Lim directed an NIH-supported project that led to the discovery and patenting of two novel autoantigen biomarkers for Primary Biliary Cholangitis (PBC), an autoimmune liver disease. His leadership in this significant project showcases his ability to lead high-impact research initiatives and contribute to important medical discoveries within the field of biotechnology.
Co-Inventor on 12 Issued U.S. Biotechnology Patents
Dr. Mark Lim is a co-inventor on 12 issued U.S. patents in the biotechnology space. These patents reflect his innovative contributions to the industry's intellectual property landscape. His work in this area underscores his ability to develop new technologies and solutions that advance scientific understanding and application in biotechnology.
Author of Peer-Reviewed Scientific Journal Articles
Dr. Mark Lim has authored more than 15 peer-reviewed scientific journal articles. These publications highlight his commitment to sharing valuable research findings with the scientific community. His contributions to scientific literature help disseminate knowledge and foster further research and advancements in biotechnology.
Leading AmberGen's MALDI-IHC Tissue Imaging Technology
Dr. Mark Lim is leading the development of AmberGen's innovative MALDI-IHC tissue imaging technology. His role in this cutting-edge project positions him at the forefront of advancements in tissue imaging, with potential implications for research and diagnostics in biotechnology. His work demonstrates a continuous dedication to pushing technological boundaries and enhancing scientific capabilities.